Bitcoin Traders Eye Risk Appetite as Abivax Rockets 38% on Phase 3 Data

Crypto News

Shares of French biotech Abivax rocketed more than 38% on June 30, 2026, one of the sharpest single-session rebounds seen in European equities this quarter. The move erased a full month of losses in a single day, reversing a slide that had wiped out 43% of the company’s value earlier in June. Fresh Phase 3 results for obefazimod, the firm’s lead ulcerative colitis therapy, drove the reversal, showing durable disease remission with no new safety signals. For desks watching risk appetite live, the snapback offered a rare pocket of conviction inside an otherwise defensive tape, and it reset the entire narrative around the stock within hours.

The rally undid the damage from a brutal June 2 session, when Abivax stock crashed 43% in a single day. Early trial data at the time had flagged a rise in malignancies among patients taking obefazimod, igniting cancer-safety fears that gutted the shares. That signal defined the stock for most of the month and kept buyers firmly on the sidelines. The concern was not trivial: an oncology red flag can stall or sink a drug program long before it ever reaches regulators. The June 2 sell-off framed everything that followed, setting the low base from which the eventual recovery would be measured.

Abivax released new Phase 3 data on Sunday, June 28, this time covering patients who had failed initial treatment. According to the company’s own disclosure, researchers reported malignancy rates within the range physicians typically observe in ulcerative colitis patients, directly countering the earlier alarm. That distinction mattered: the updated read reframed the June 2 signal as noise rather than a structural risk, calming the safety concern that had triggered the sell-off. Investors treated the release as a clean answer to the central question hanging over the program. The disclosure positioned the numbers as evidence the treatment remains within accepted clinical safety bounds.

The efficacy figures reinforced the case. Among patients who had failed initial treatment, 37.2% reached clinical remission and 34.5% reached endoscopic remission by week 44, per the company’s disclosure. Those readings carry weight because harder-to-treat patients are precisely where many therapies falter, and durable remission at that stage strengthens the commercial argument. Endoscopic remission, confirmed by direct visualization of the intestinal lining rather than symptom relief alone, is the stricter bar of the two. Clearing both thresholds in a difficult population handed analysts a concrete data point to anchor revised models, and gave the market a reason to look past the June scare entirely.

Zoom out, and the scale of the move is striking: Abivax shares have now climbed more than 1,730% over the past year, a gain that dwarfs almost anything in mainstream equity benchmarks. That trajectory reflects a stock repeatedly repriced on binary clinical events, swinging violently between conviction and doubt. Such returns are unusual outside the most speculative corners of the market, and they underline how much of the company’s valuation now rides on data readouts rather than revenue. The one-day 38% jump is best understood inside that context — a high-beta name where a single disclosure can reset the entire investment thesis overnight.

Wall Street did not converge on a single verdict. Citizens raised its price target to $187 and kept an Outperform rating, citing the drug’s placebo-adjusted remission benefit as the core bull case. Wedbush took the cautious side, upgrading the stock from Underperform to Neutral but cutting its target to $90, pointing to lingering malignancy questions at the 50 mg dose as a regulatory risk. The gap between those two targets captures the unresolved debate. Abivax still plans to file a new drug application with the U.S. FDA in the fourth quarter of 2026, a milestone that will keep the shares sensitive to any additional safety data until then.

Our reading across these threads is that June’s round trip in Abivax is a case study in how fast a single data point can reset risk pricing — a dynamic crypto traders know intimately. That relevance is sharper right now: COINOTAG’s aggregate market data shows the Fear & Greed Index pinned at 11 out of 100, deep in Extreme Fear, with Bitcoin dominance at 69.7% and total crypto market capitalization near $1.69 trillion. In that regime, capital crowds into perceived safety and shuns high-beta altcoin bets, much as it fled Abivax before the reversal. No all-time-high chase — whether run by a human or an AI trading bot — survives when a binary risk sits one headline away, the same repricing logic that stress-tests algorithmic stablecoins.